Showing results (141-150 of 238) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2005
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumorsDik J Kwekkeboom, Jaap J Teunissen, Willem H Bakker, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 28, 2009
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotateFlavio Forrer, Eric P Krenning, Peter P Kooij, et al.
Clinical Endocrinology|August 3, 2005
The somatostatin analogue SOM230, compared with octreotide, induces differential effects in several metabolic pathways in acromegalic patientsJoost van der Hoek, Aart-Jan van der Lelij, Richard A Feelders, et al.
Endoscopy International Open|July 18, 2022
Epidemiological, clinical and endoscopic characteristics of colorectal neuroendocrine neoplasms: a population-based study in the NetherlandsAnkie Reumkens, Prapto Sastrowijoto, Heike I Grabsch, et al.
Drugs|December 19, 2018
Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future PerspectivesAura D Herrera-Martínez, Johannes Hofland, Leo J Hofland, et al.
Journal of Neuroendocrinology|April 14, 2026
The effect of LysaKare infusion on serum potassium levels in patients with gastroenteropancreatic neuroendocrine tumours eligible for treatment with [<sup>177</sup>Lu]Lu-DOTA-TATE: A post-authorisation safety studyJohannes Hofland, Chiara Maria Grana, Martin O Weickert, et al.
Plos One|August 12, 2014
Inhibin alpha-subunit (INHA) expression in adrenocortical cancer is linked to genetic and epigenetic INHA promoter variationJohannes Hofland, Jacobie Steenbergen, Jacoba M Voorsluijs, et al.
Frontiers in Endocrinology|May 24, 2023
Epigenetic regulation of SST<sub>2</sub> expression in small intestinal neuroendocrine tumorsMaria J Klomp, Julie Refardt, Peter M van Koetsveld, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 1, 2022
Induction therapy with <sup>177</sup>Lu-DOTATATE procures long-term survival in locally advanced or oligometastatic pancreatic neuroendocrine neoplasm patientsNoémie S Minczeles, Casper H J van Eijck, Marjon J van Gils, et al.
The Journal of Pathology. Clinical Research|November 8, 2024
Clinicopathological and epigenetic differences between primary neuroendocrine tumors and neuroendocrine metastases in the ovaryMerijn C F Mulders, Anna Vera D Verschuur, Quido G de Lussanet de la Sablonière, et al.
Pageof 24